Viewing Study NCT06684106


Ignite Creation Date: 2025-12-26 @ 5:23 PM
Ignite Modification Date: 2026-01-24 @ 12:04 PM
Study NCT ID: NCT06684106
Status: RECRUITING
Last Update Posted: 2025-09-19
First Post: 2024-11-04
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose Tolerance
Sponsor: First Affiliated Hospital Xi'an Jiaotong University
Organization:

Study Overview

Official Title: Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose Tolerance: A Randomized Controlled Clinical Trial
Status: RECRUITING
Status Verified Date: 2025-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: URSTAR
Brief Summary: The purpose of this clinical trial is to understand whether the drug Ursodeoxycholic acid (UDCA) can prevent glucose intolerance in participants with hyperlipidemia who are taking statins. It will also assess the safety of UDCA. The primary questions it aims to answer are:

* Will UDCA reduce the incidence of glucose intolerance in participants taking oral statins?
* Will the use of UDCA decrease other adverse events in patients taking oral statins?

Participants will:

* Take Atorvastatin combined with UDCA or a placebo daily for 6 months
* Have follow-up visits on day 40, day 110, and day 180 Have their examination indicators recorded.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
CSCF2022B04 OTHER_GRANT 2022 Chinese Society of Cardiology's Foundation View